Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy

NCT04137640 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

152

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: palbociclib combined with letrozole
DRUG: epirubicin combined with cyclophosphamide and sequential docetaxel

Sponsor

Shengjing Hospital